Barinthus Biotherapeutics plc (FRA:2AB)
Germany · Delayed Price · Currency is EUR 0.5750
+0.0400 (7.48%)
Last updated: Aug 27, 2026, 8:03 AM CET
Barinthus Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | 14.97 | 0.8 | 44.7 | 0.27 | |
Revenue Growth | - | - | 1766.46% | -98.21% | 16580.22% | -94.44% |
Cost of Revenue | -8.59 | 0.13 | 1.68 | 2.01 | 42.35 | 20.37 |
Gross Profit | 8.59 | -0.13 | 13.29 | -1.21 | 2.35 | -20.1 |
Selling, General & Admin | 16.06 | 35.01 | 23.54 | 39.79 | 6.47 | 25.12 |
Research & Development | 24.88 | 23.43 | 36.57 | 39.4 | -1.24 | -4 |
Other Operating Expenses | -0.22 | -0.51 | -1.18 | - | - | - |
Operating Expenses | 40.72 | 57.94 | 58.94 | 79.19 | 5.23 | 21.12 |
Operating Income | -32.13 | -58.07 | -45.65 | -80.4 | -2.87 | -41.22 |
Interest Expense | -0.05 | -0.05 | -0.05 | -0.03 | -0.02 | -2.67 |
Interest & Investment Income | 1.57 | 1.96 | 2.68 | 2.88 | 3.1 | 0 |
Currency Exchange Gain (Loss) | - | - | - | - | - | 0.21 |
Other Non Operating Income (Expenses) | -0.31 | 0.02 | 0.14 | 1.08 | 0.57 | 6.33 |
EBT Excluding Unusual Items | -30.93 | -56.15 | -42.89 | -76.47 | 0.78 | -37.35 |
Impairment of Goodwill | - | - | -12.21 | - | - | - |
Asset Writedown | -10.46 | -10.46 | -5.26 | - | - | - |
Other Unusual Items | -0.59 | -0.03 | -0.87 | -0.06 | 0.07 | -13.79 |
Pretax Income | -41.97 | -66.63 | -61.23 | -76.52 | 0.85 | -51.14 |
Income Tax Expense | -0.17 | -0.18 | -0.04 | -3.08 | -4.47 | -0.03 |
Earnings From Continuing Operations | -41.81 | -66.46 | -61.18 | -73.45 | 5.32 | -51.11 |
Minority Interest in Earnings | 0.04 | 0.03 | 0.11 | 0.1 | 0.02 | 0.25 |
Net Income | -41.77 | -66.43 | -61.07 | -73.35 | 5.34 | -50.87 |
Net Income to Common | -41.77 | -66.43 | -61.07 | -73.35 | 5.34 | -50.87 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 41 | 41 | 39 | 38 | 37 | 26 |
Shares Outstanding (Diluted) | 41 | 41 | 39 | 38 | 38 | 26 |
Shares Change | 1.88% | 3.00% | 2.50% | 0.57% | 47.40% | 227.59% |
EPS (Basic) | -1.02 | -1.64 | -1.55 | -1.91 | 0.14 | -1.96 |
EPS (Diluted) | -1.02 | -1.64 | -1.55 | -1.91 | 0.14 | -1.96 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -26.43 | -48.02 | -29.83 | -56.34 | -20.57 | -33.73 |
Free Cash Flow Per Share | -0.65 | -1.19 | -0.76 | -1.47 | -0.54 | -1.30 |
Gross Margin | - | - | 88.78% | -150.75% | 5.26% | - |
Operating Margin | - | - | -304.98% | -10024.69% | -6.43% | -15380.60% |
Profit Margin | - | - | -408.00% | -9145.51% | 11.95% | -18979.48% |
Free Cash Flow Margin | - | - | -199.29% | -7024.69% | -46.01% | -12585.45% |
EBITDA | -31.24 | -55.22 | -43.05 | -78.17 | -1.75 | -40.82 |
EBITDA Margin | - | - | -287.61% | - | -3.92% | - |
D&A For EBITDA | 0.89 | 2.85 | 2.6 | 2.23 | 1.12 | 0.4 |
EBIT | -32.13 | -58.07 | -45.65 | -80.4 | -2.87 | -41.22 |
EBIT Margin | - | - | - | - | -6.43% | - |
Revenue as Reported | - | - | 14.97 | 0.8 | 44.7 | 0.27 |